Form 4: Adaptive Biotechnologies Executive Stock Transaction

Chief People Officer Francis Lo executed a series of stock option exercises and sales under a Rule 10b5-1 trading plan.

Summary

• Francis Lo, Chief People Officer of Adaptive Biotechnologies, exercised stock options for a total of 19,521 shares at various strike prices ranging from $3.99 to $12.14.
• Following the exercises, the executive sold 39,741 shares of common stock at a price of $17.49 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025.
• The reporting person retains direct ownership of 250,934 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-established 10b5-1 plan, which is a routine administrative action.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating the sales were not based on non-public information.
• The executive maintains a significant equity stake of 250,934 shares, aligning interests with shareholders.

Negatives

• The executive reduced their direct beneficial ownership through the sale of 39,741 shares.

Risks

• Future stock price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the executive or the company.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard corporate practice and generally does not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for executives in the biotechnology sector to manage personal liquidity while avoiding insider trading concerns.

Related Party Transactions

• The reporting person holds 2,500 shares indirectly through their spouse, You Jin Lee.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Options, Rule 10b5-1